Bank of New York Mellon’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $118M | Sell |
699,125
-3,367
| -0.5% | -$500K | 0.02% | 592 |
|
|
2026
Q1 | $92.5M | Sell |
702,492
-36,184
| -5% | -$4.8M | 0.02% | 671 |
|
|
2025
Q4 | $105M | Sell |
738,676
-22,720
| -3% | -$3.29M | 0.02% | 630 |
|
|
2025
Q3 | $107M | Sell |
761,396
-17,234
| -2% | -$2.34M | 0.02% | 614 |
|
|
2025
Q2 | $97.9M | Sell |
778,630
-50,052
| -6% | -$5.74M | 0.02% | 640 |
|
|
2025
Q1 | $91.7M | Sell |
828,682
-41,608
| -5% | -$5.27M | 0.02% | 650 |
|
|
2024
Q4 | $119M | Buy |
870,290
+12,040
| +1% | +$1.49M | 0.02% | 570 |
|
|
2024
Q3 | $98.9M | Sell |
858,250
-76,154
| -8% | -$10.4M | 0.02% | 651 |
|
|
2024
Q2 | $129M | Buy |
934,404
+13,069
| +1% | +$1.79M | 0.02% | 524 |
|
|
2024
Q1 | $127M | Sell |
921,335
-57,725
| -6% | -$7.88M | 0.02% | 548 |
|
|
2023
Q4 | $129M | Sell |
979,060
-560,332
| -36% | -$64.5M | 0.03% | 530 |
|
|
2023
Q3 | $173M | Sell |
1,539,392
-49,823
| -3% | -$5.25M | 0.04% | 399 |
|
|
2023
Q2 | $150M | Sell |
1,589,215
-62,794
| -4% | -$6.14M | 0.03% | 458 |
|
|
2023
Q1 | $167M | Sell |
1,652,009
-32,714
| -2% | -$3.4M | 0.04% | 426 |
|
|
2022
Q4 | $201M | Sell |
1,684,723
-56,232
| -3% | -$6.59M | 0.05% | 356 |
|
|
2022
Q3 | $185M | Buy |
1,740,955
+37,538
| +2% | +$3.81M | 0.04% | 377 |
|
|
2022
Q2 | $166M | Buy |
1,703,417
+324
| +0% | +$29.9K | 0.04% | 421 |
|
|
2022
Q1 | $160M | Sell |
1,703,093
-158,896
| -9% | -$13.5M | 0.03% | 481 |
|
|
2021
Q4 | $159M | Sell |
1,861,989
-40,058
| -2% | -$3.68M | 0.03% | 504 |
|
|
2021
Q3 | $182M | Sell |
1,902,047
-113,584
| -6% | -$10.7M | 0.04% | 440 |
|
|
2021
Q2 | $196M | Buy |
2,015,631
+83,484
| +4% | +$8M | 0.04% | 414 |
|
|
2021
Q1 | $188M | Buy |
1,932,147
+760,465
| +65% | +$79.7M | 0.04% | 423 |
|
|
2020
Q4 | $112M | Buy |
1,171,682
+58,975
| +5% | +$5.7M | 0.02% | 605 |
|
|
2020
Q3 | $107M | Buy |
1,112,707
+140,008
| +14% | +$16.2M | 0.03% | 544 |
|
|
2020
Q2 | $119M | Buy |
972,699
+149,722
| +18% | +$16.5M | 0.03% | 474 |
|
|
2020
Q1 | $71.2M | Buy |
822,977
+194,104
| +31% | +$19M | 0.02% | 597 |
|
|
2019
Q4 | $67.6M | Sell |
628,873
-298,888
| -32% | -$31.3M | 0.02% | 803 |
|
|
2019
Q3 | $83.6M | Sell |
927,761
-25,181
| -3% | -$2.35M | 0.02% | 668 |
|
|
2019
Q2 | $80.5M | Sell |
952,942
-1,728
| -0.2% | -$142K | 0.02% | 702 |
|
|
2019
Q1 | $84.1M | Sell |
954,670
-14,763
| -2% | -$1.23M | 0.02% | 674 |
|
|
2018
Q4 | $69.2M | Sell |
969,433
-40,421
| -4% | -$3.87M | 0.02% | 708 |
|
|
2018
Q3 | $124M | Sell |
1,009,854
-208,984
| -17% | -$23.7M | 0.03% | 527 |
|
|
2018
Q2 | $120M | Sell |
1,218,838
-120,177
| -9% | -$10.8M | 0.03% | 518 |
|
|
2018
Q1 | $111M | Sell |
1,339,015
-146,639
| -10% | -$12.4M | 0.03% | 540 |
|
|
2017
Q4 | $115M | Sell |
1,485,654
-347,723
| -19% | -$23.7M | 0.03% | 559 |
|
|
2017
Q3 | $112M | Sell |
1,833,377
-356,048
| -16% | -$18.8M | 0.03% | 545 |
|
|
2017
Q2 | $101M | Buy |
2,189,425
+283,008
| +15% | +$13.7M | 0.03% | 581 |
|
|
2017
Q1 | $82.5M | Buy |
1,906,417
+505,604
| +36% | +$21.7M | 0.02% | 676 |
|
|
2016
Q4 | $54.2M | Sell |
1,400,813
-5,225
| -0.4% | -$237K | 0.02% | 889 |
|
|
2016
Q3 | $71.2M | Buy |
1,406,038
+990,488
| +238% | +$49.3M | 0.02% | 690 |
|
|
2016
Q2 | $18.9M | Sell |
415,550
-36,248
| -8% | -$1.67M | 0.01% | 1439 |
|
|
2016
Q1 | $17.9M | Buy |
451,798
+7,885
| +2% | +$313K | 0.01% | 1483 |
|
|
2015
Q4 | $25.1M | Buy |
443,913
+26,525
| +6% | +$1.35M | 0.01% | 1252 |
|
|
2015
Q3 | $16.6M | Sell |
417,388
-55,591
| -12% | -$2.69M | 0.01% | 1533 |
|
|
2015
Q2 | $22.6M | Buy |
472,979
+36,068
| +8% | +$1.53M | 0.01% | 1401 |
|
|
2015
Q1 | $17.3M | Buy |
436,911
+48,703
| +13% | +$1.74M | ﹤0.01% | 1605 |
|
|
2014
Q4 | $8.67M | Sell |
388,208
-1,280
| -0.3% | -$24.3K | ﹤0.01% | 1995 |
|
|
2014
Q3 | $6.1M | Buy |
389,488
+19,170
| +5% | +$287K | ﹤0.01% | 2187 |
|
|
2014
Q2 | $5.49M | Buy |
370,318
+3,322
| +0.9% | +$46.9K | ﹤0.01% | 2279 |
|
|
2014
Q1 | $5.91M | Buy |
366,996
+18,518
| +5% | +$317K | ﹤0.01% | 2221 |
|
|
2013
Q4 | $3.25M | Buy |
348,478
+7,835
| +2% | +$76.5K | ﹤0.01% | 2566 |
|
|
2013
Q3 | $3.86M | Sell |
340,643
-169,350
| -33% | -$2.33M | ﹤0.01% | 2397 |
|
|
2013
Q2 | $6.82M | Buy |
+509,993
| New | +$6.27M | ﹤0.01% | 2012 |
|
Other funds holding NBIX
IC
Bank of New York Mellon's NBIX Position: Q2 2026 in Review
Bank of New York Mellon reduced its Neurocrine Biosciences (NBIX) stake by 0.48% in Q2 2026, selling an estimated $500K and leaving 699,125 shares worth $118M. The position accounts for 0.02% of the portfolio, ranked #592.
Bank of New York Mellon first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. The position peaked at $201M in Q4 2022. 526 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Bank of New York Mellon held 699,125 shares of Neurocrine Biosciences worth $118M as of Q2 2026.
- Bank of New York Mellon sold 3,367 Neurocrine Biosciences shares in Q2 2026, an estimated $500K.
- Neurocrine Biosciences made up 0.02% of Bank of New York Mellon's portfolio in Q2 2026, its #592 holding.
- Bank of New York Mellon first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's Neurocrine Biosciences position peaked at $201M in Q4 2022.
- 526 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.